Earnings Call Summary | Surgery Partners(SGRY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Surgery Partners(SGRY.US) Q1 2024 Earnings Conference
The following is a summary of the Surgery Partners, Inc. (SGRY) Q1 2024 Earnings Call Transcript:
以下是外科合作伙伴公司(SGRY)2024年第一季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
Surgery Partners Q1 net revenue was approximately $717 million, a 7.7% growth from the prior year.
Adjusted EBITDA of $97.5 million, an 8.2% growth over the last year's quarter.
EBITDA margins improved by 10 basis points to 13.6%.
The company increased its full-year revenue outlook to at least $3.05 billion, representing 11% growth.
Adjusted full-year EBITDA outlook increased to $505 million, a growth of at least 15%.
Company's supply expense was essentially unchanged and supply cost per case decreased 1.4%.
The company's operating and free cash flow for 2023 exceeded previous years due to timing and growth.
A true up of provider taxes impacted the financials in the first quarter.
Surgery Partners第一季度的淨收入約爲7.17億美元,比上年增長7.7%。
調整後的息稅折舊攤銷前利潤爲9,750萬美元,比去年同期增長8.2%。
息稅折舊攤銷前利潤率提高了10個點子至13.6%。
該公司將其全年收入展望提高至至少30.5億美元,增長11%。
調整後的全年息稅折舊攤銷前利潤展望增至5.05億美元,增長至少15%。
公司的供應費用基本保持不變,每箱供應成本下降了1.4%。
由於時機和增長,該公司2023年的運營和自由現金流超過了往年。
供應商稅的真正上漲影響了第一季度的財務狀況。
Business Progress:
業務進展:
Surgery Partners plans $200 to $250 million in acquisition closures in Q2.
They successfully recruited around 200 new physicians, especially orthopedic surgeons, in Q1.
The focus on higher acuity procedures saw total joint replacements increase by 54%.
The company is expanding initiatives to acquire more surgical centers.
There's an ongoing plan to increase investment in infrastructural and operational improvements.
Surgery Partners established new facilities expected to have positive EBITDA by end of the first year.
Continued focus on high acuity cases, expecting a high single-digit growth by end of year.
Managed care negotiations are ongoing with a focus on providing value; the company is 50% cheaper on average than peers.
Company reiterated its cash flow guidance for the year, expecting it to stay between 140 to 160 million.
Continual provision of high-quality, lower-cost clinical care in their facilities is a priority.
Surgery Partners計劃在第二季度完成2億至2.5億美元的收購。
他們在第一季度成功招募了大約200名新醫生,尤其是整形外科醫生。
對更高敏度手術的關注使關節置換總數增加了54%。
該公司正在擴大收購更多外科中心的舉措。
目前正在計劃增加對基礎設施和運營改善的投資。
Surgery Partners建立了新設施,預計到第一年年底的息稅折舊攤銷前利潤將爲正數。
繼續關注高敏度病例,預計到年底將實現較高的個位數增長。
管理式醫療談判正在進行中,重點是提供價值;該公司的平均價格比同行便宜50%。
公司重申了其今年的現金流指導,預計將保持在1.4億至1.6億美元之間。
在其設施中持續提供高質量、低成本的臨床護理是當務之急。
More details: Surgery Partners IR
更多詳情: 手術合作伙伴 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。